Maze Therapeutics, Inc.
MAZECIK 0001842295 · last filing Jul 2, 2026
Insider signal
trades dated in the last 90 days · non-derivative only
22,109 bought / 56,610 sold
net −34,501 sh · −$1.45M
- buys
- 2
- sells
- 6
- insiders active
- 3
Filing tape
Filed Thu, Jul 2, 2026
- −0 sh · $284.6K
Bernstein Harold — President, R&D & CMO
- Exercised14,609Common Stock@ $10.42→ 14,609 held
- Sold13,409Common Stock@ $29.87→ 1,200 held
- Sold1,200Common Stock@ $30.34→ 0 held
- Exercised14,609Stock Option (Right to Buy)→ 192,945 held
- −34,501 sh · $1.03M
Coloma Jason V — Chief Executive Officer · Director
- Sold2,593Common Stock@ $29.98→ 23,337 held
- Sold30,311Common Stock@ $29.95→ 288,768 held
- Sold1,597Common Stock@ $30.44→ 287,171 held
Filed Wed, Jul 1, 2026
- −0 sh · $132.0K
Dandekar Atul — CSBO
- Exercised7,500Common Stock@ $10.42→ 33,750 held
- Sold7,500Common Stock@ $28.02→ 26,250 held
- Exercised7,500Stock Option (Right to Buy)→ 29,143 held
Insiders on this tape
- Bernstein HaroldPresident, R&D & CMO
- Coloma Jason VChief Executive Officer · Director
- Dandekar AtulCSBO
Informational data only — not investment advice.
The institutional holdings shown here are aggregated from third-party public regulatory filings (such as SEC Form 13F). These filings are reported with a delay (generally up to 45 days after each quarter-end), are backward-looking, and may exclude short positions, non-U.S. holdings, cash, and other assets. The data may contain errors, omissions, misclassifications, or gaps, and may not reflect a manager's current positions.
All figures are provided on an "as is" basis for general information only. Nothing on this page is financial, investment, or trading advice, a recommendation, or an endorsement of any security, manager, or strategy. Do not rely on it. Independently verify any figure against the original filings and consult a qualified professional before making any financial decision. Your use is subject to our Terms of Service.